In recent years there has been an upsurge of new biologics and small-molecule therapies for ulcerative colitis (UC), making it challenging for the UC interdisciplinary care team (such as gastroenterologists, physician associates, and nurse practitioners) to stay abreast of these advances and navigate the complexity of treatment decisions. Treatment selection must now include consideration of many patient and disease factors and incorporate a shared decision-making (SDM) model. Given the ongoing burden associated with UC and its comorbidities, including isolated proctitis (IP), it is essential that gastroenterologists be able to manage UC effectively with optimal utilization of available agents.
In this CME Outfitters Infographic, expert faculty will explore the role of new advanced therapies in UC treatment algorithms, facilitating the transition to these therapies in patients with UC who are non-/under-responsive to traditional treatments, and utilizing traditional treatments as well as available biologics and small-molecule therapies to optimize outcomes in patients with IP.
At the conclusion of this activity, learners will be able to better:
Supported by educational grant from Pfizer Inc.
Gastroenterologists, nurse practitioners (NPs), and physician associates (PAs)
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 1.00 contact hours.
California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters, LLC’s provider number is CEP15510.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 12/27/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Afzali reports the following financial relationships:
Advisory Board and Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Research Support: AbbVie Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; Lilly; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Speakers Bureau: AbbVie Inc.; Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc.
Other financial or material support: Co-Founder/Board Member: IBD Horizons and Scrubs & Heels Foundation
The following individuals have no financial relationships to disclose:
Rebecca Vargas-Jackson, MD (Peer Reviewer)
Shirley Michelle Franks, MSN, APRN, FNP-BC (Peer Reviewer)
Susan Perry (Planning Committee)
Kasey Brandt, PharmD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
*All identified conflicts of interest have been mitigated.
Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Call us at 877.CME.PROS (877.263.7767).
IN-010-123124-02